Results 71 to 80 of about 2,201,777 (199)

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. [PDF]

, 2022
BACKGROUND Studies of targeted therapy resistance in lung cancer have primarily focused on single gene alterations. Based on prior work implicating APOBEC mutagenesis in histological transformation of EGFR-mutant lung cancers, we hypothesized that ...
Choudhury, N J, Patel, J, Berger, M F, Chandarlapaty, S, Ng, C K Y, Lovly, C M, Zhang, Y-K, Heller, G, Gazzo, A, Ladanyi, M, Marra, A, Pei, X, Reis-Filho, J S, Yu, H A, Selenica, P, Rudin, C M, Falcon, C J, Curry, M, Zhu, Y   +18 more
core   +2 more sources

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study

Lung Cancer
Resistance mechanisms (RMs) inevitably develop during osimertinib treatment in EGFR mutation positive (EGFRm+) NSCLC, and may guide subsequent therapy. We hypothesized that a complete RM analysis requires next-generation sequencing (NGS) of tumor tissue and plasma in patients experiencing disease progression (PD) on first-line osimertinib.At time of PD
J.W.T. van der Wel, S.M. Ernst, M. Jebbink, D. van den Broek, S.K. Badrising, L.C. Steinbusch, G. Ruiter, W.S.M.E. Theelen, B.A.M.H. van Veggel, J. Smit, A.M. Dingemans, M.S. Paats, H.J. Dubbink, S.M.S. Hashemi, T. Radonic, D. Cohen, A.J. van der Wekken, A. ter Elst, W. Timens, L.E. Hendriks, E.J.M. Speel, M.M.J. Disselhorst, A. Welling, F. van der Meer, L.J.W. Bosch, K. Monkhorst, M.C. Boelens, E.F. Smit, A.J. de Langen   +28 more
openaire   +7 more sources

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, EarlyView.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

Frontiers in Molecular Biosciences, 2021
Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor.
Xue Yang, Yang Xia, Liyan Xu, Li Liang, Minglei Zhuo, Meina Wu, Tongtong An, Ziping Wang, Yuyan Wang, Jianjie Li, Jia Zhong, Hanxiao Chen, Bo Jia, Jingjing Wang, Jun Zhao   +14 more
doaj   +1 more source

LINC01605 Predicts the Poor Prognosis of Non‐Small Cell Lung Cancer and Promotes Chemotherapy Resistance by Regulating miR‐7111‐5p/ELK1

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Non‐small cell lung cancer (NSCLC) is characterized by high incidence, mortality, and poor patient prognosis, with chemotherapy resistance being a common challenge. This research intends to identify key molecules involved in NSCLC and elucidate the regulatory role of the LINC01605/miR‐7111‐5p/ELK1 axis in chemotherapy resistance. LINC01605 and
Fang Zhang, Zhi‐Liang Yang, Tian‐Tian Qin, Guo‐Jun Zhang, Xiang Li   +4 more
wiley   +1 more source

Restoration of Osimertinib sensitivity in lung cancer through BRD4 inhibitor-mediated depalmitoylation of mutant EGFR via APT1

npj Precision Oncology
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations initially responds to the third-generation EGFR-tyrosine kinase inhibitor (TKI) Osimertinib.
Wolong Zhou, Shaoqiang Wang, Zhenyu Zhang, Linfeng Li, Jiebo Zhu, Hang Lin, Heng Zhang   +6 more
doaj   +1 more source

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

The Journal of Pathology, EarlyView.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti, Martina Brigida Romanello, Luca Agnelli, Matteo Orlandi, Luca Bertoli, Sara Picinoli, Irene Pezzali, Giulio Eugenio Mandelli, Daniela Medicina, Giovanni Ribaudo, Adele Busico, Elena Conca, Vilma Pellegrini, Piera Balzarini, Daniele Gallucci, Anna Di Matteo, Davide Lombardi, Claudia Ghigna, Giancarlo Pruneri, Alessandra Gianoncelli, Marzia Rossato, William Vermi   +21 more
wiley   +1 more source

The Evolving Landscape of Resistance to Osimertinib [PDF]

Journal of Thoracic Oncology, 2020
Adam J, Schoenfeld, Helena A, Yu
openaire   +2 more sources

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

Precision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan, Bushra Waheed, Rani Akbar, Daniel Dubwa   +3 more
wiley   +1 more source

Magnetothermal‐responsive drug release bone cement based on EGFR‐mutated lung cancer bone metastases

VIEW, EarlyView.
A novel magnetothermal‐responsive bone cement was developed by integrating PMMA/CPC/Osimertinib matrix with Fe3O4@SiO2@Zol nanomaterials. This dual‐drug system achieves controlled release, combining excellent mechanical properties with potent anti‐tumor activity and bone regulation for treating EGFR‐mutated LC‐BoM.
Kandi Xu, Kai Li, Hao Wang, Lishu Zhao, Xinyue Liu, Yujin Liu, Li Ye, Wengang Zhang, Zhimin Chen, Xuyang Chen, Yujie Li, Qianqian Zhang, Wencheng Zhao, Xuebin Zheng, Yu Chen, Yayi He   +15 more
wiley   +1 more source